See more : Nihon Kagaku Sangyo Co., Ltd. (4094.T) Income Statement Analysis – Financial Results
Complete financial analysis of Charmacy Pharmaceutical Co., Ltd. (2289.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Charmacy Pharmaceutical Co., Ltd., a leading company in the Medical – Distribution industry within the Healthcare sector.
- Gosun Holding Co., Ltd. (000971.SZ) Income Statement Analysis – Financial Results
- Cineworld Group plc (CNNWQ) Income Statement Analysis – Financial Results
- Xiamen Tungsten Co., Ltd. (600549.SS) Income Statement Analysis – Financial Results
- Betacom S.A. (BCM.WA) Income Statement Analysis – Financial Results
- Gigastone Corporation (5262.TWO) Income Statement Analysis – Financial Results
Charmacy Pharmaceutical Co., Ltd. (2289.HK)
About Charmacy Pharmaceutical Co., Ltd.
Charmacy Pharmaceutical Co., Ltd. engages in the trading of pharmaceutical products in the People's Republic of China. The company offers western medicines, Chinese patent medicines, healthcare products, and related consulting services to downstream distributors and terminal chemists. It also operates Charmacy e-Medicine, a B2B e-commerce platform to place orders online and make inquiries and payments. The company was formerly known as Chuangmei Pharmaceutical Co., Ltd. and changed its name to Charmacy Pharmaceutical Co., Ltd. in July 2016. Charmacy Pharmaceutical Co., Ltd. was incorporated in 1984 and is headquartered in Shantou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.40B | 4.18B | 3.79B | 3.99B | 3.49B | 3.94B | 4.10B | 3.67B | 3.40B | 3.01B | 2.40B |
| Cost of Revenue | 4.11B | 3.91B | 3.56B | 3.75B | 3.27B | 3.70B | 3.89B | 3.49B | 3.23B | 2.88B | 2.30B |
| Gross Profit | 292.74M | 268.61M | 234.12M | 237.40M | 220.65M | 235.12M | 207.42M | 179.85M | 164.70M | 136.44M | 103.98M |
| Gross Profit Ratio | 6.65% | 6.43% | 6.17% | 5.95% | 6.32% | 5.97% | 5.06% | 4.90% | 4.85% | 4.53% | 4.33% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 133.24M | 49.65M | 48.40M | 45.70M | 46.50M | 54.16M | 49.50M | 38.76M | 40.38M | 37.16M | 33.97M |
| Selling & Marketing | 37.56M | 112.92M | 103.45M | 85.97M | 77.40M | 73.98M | 68.08M | 51.78M | 40.30M | 35.76M | 25.14M |
| SG&A | 170.80M | 165.05M | 151.56M | 143.04M | 128.15M | 130.19M | 119.56M | 92.65M | 80.68M | 72.92M | 59.11M |
| Other Expenses | 51.38M | -372.28K | -128.44K | -37.00K | 65.91K | 219.11K | 239.40K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 226.55M | 116.08M | 163.42M | 154.94M | 138.80M | 143.55M | 125.55M | 90.24M | 103.68M | 72.41M | 58.10M |
| Cost & Expenses | 4.34B | 4.02B | 3.72B | 3.91B | 3.41B | 3.84B | 4.01B | 3.58B | 3.34B | 2.95B | 2.36B |
| Interest Income | 4.30M | 30.47M | 37.72M | 27.72M | 26.80M | 27.92M | 22.01M | 13.53M | 19.45M | 18.10M | 16.56M |
| Interest Expense | 40.79M | 35.07M | 41.52M | 31.74M | 30.42M | 31.09M | 25.39M | 16.61M | 24.10M | 22.83M | 0.00 |
| Depreciation & Amortization | 26.47M | 30.68M | 32.03M | 24.55M | 23.94M | 18.44M | 14.12M | 12.21M | 8.98M | 9.73M | 9.97M |
| EBITDA | 136.92M | 119.19M | 107.55M | 111.03M | 110.15M | 113.81M | 99.39M | 94.94M | 93.01M | 73.25M | 54.84M |
| EBITDA Ratio | 3.11% | 2.85% | 2.73% | 2.75% | 3.04% | 2.99% | 2.39% | 2.59% | 2.74% | 2.43% | 2.28% |
| Operating Income | 66.19M | 93.49M | 74.42M | 88.08M | 85.20M | 99.08M | 83.72M | 83.46M | 84.03M | 63.52M | 44.87M |
| Operating Income Ratio | 1.50% | 2.24% | 1.96% | 2.21% | 2.44% | 2.52% | 2.04% | 2.27% | 2.47% | 2.11% | 1.87% |
| Total Other Income/Expenses | 1.22M | 28.57M | 592.68K | -33.33M | 638.76K | -35.43M | 3.93M | 2.92M | -42.45M | -17.59M | -15.56M |
| Income Before Tax | 67.42M | 122.05M | 32.98M | 54.74M | 55.04M | 63.66M | 59.86M | 76.08M | 41.58M | 45.94M | 29.31M |
| Income Before Tax Ratio | 1.53% | 2.92% | 0.87% | 1.37% | 1.58% | 1.62% | 1.46% | 2.07% | 1.22% | 1.52% | 1.22% |
| Income Tax Expense | 16.07M | 31.67M | 9.83M | 14.19M | 14.89M | 18.89M | 15.56M | 19.62M | 15.22M | 9.49M | 7.10M |
| Net Income | 51.34M | 90.47M | 23.15M | 40.56M | 40.15M | 45.43M | 44.76M | 59.35M | 26.36M | 36.45M | 22.22M |
| Net Income Ratio | 1.17% | 2.17% | 0.61% | 1.02% | 1.15% | 1.15% | 1.09% | 1.62% | 0.78% | 1.21% | 0.93% |
| EPS | 0.48 | 0.84 | 0.21 | 0.38 | 0.37 | 0.42 | 0.41 | 0.52 | 0.32 | 0.46 | 0.00 |
| EPS Diluted | 0.48 | 0.84 | 0.21 | 0.38 | 0.37 | 0.42 | 0.41 | 0.52 | 0.32 | 0.46 | 0.00 |
| Weighted Avg Shares Out | 108.00M | 107.99M | 107.99M | 108.01M | 108.00M | 107.99M | 108.01M | 107.99M | 81.61M | 80.00M | 0.00 |
| Weighted Avg Shares Out (Dil) | 108.00M | 107.99M | 107.99M | 108.01M | 108.00M | 107.99M | 108.01M | 107.99M | 81.61M | 80.00M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports